Cover Image
市場調查報告書

癌症性疼痛治療藥的全球市場 (2015∼2019年)

Global Cancer Pain Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 350456
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
Back to Top
癌症性疼痛治療藥的全球市場 (2015∼2019年) Global Cancer Pain Therapeutics Market 2015-2019
出版日期: 2016年01月20日 內容資訊: 英文 61 Pages
簡介

癌症性疼痛,根據癌症的分期、種類有急性疼痛和慢性疼痛。腫瘤壓迫到骨頭、神經和其他人體組織,發生癌症性疼痛。癌症性疼痛的管理,不僅對患者,對於多年持續穩定狀態的患者來說也是不可缺少的東西。NSAID (非類固醇系抗發炎藥) 和類鴉片物質,使用了疼痛治療用佐劑 (補助劑) 等的藥理介入,用於癌症性止痛。全球癌症性疼痛治療藥的市場,預計2016∼2020年以9.08%的年複合成長率(CAGR) 成長。

本報告提供全球癌症性疼痛治療藥的市場相關分析,市場概要和結構,市場規模趨勢 (今後5年的預測值),各類藥物、各地區的詳細內容趨勢,推動、阻礙市場要素與其影響力,主要企業簡介,今後的市場機會等調查評估。

第1章 摘要整理

  • 分析結果的概要

第2章 分析範圍

  • 分析概要
  • 大供應商的主要產品

第3章 市場分析技術

  • 分析方法
  • 經濟指標

第4章 簡介

  • 市場趨勢的概要

第5章 疾病概要

  • 疾病的概要
  • 前兆、症狀
  • 癌症性疼痛的原因
  • 癌症性疼痛的評估
  • 治療
  • 流行病學

第6章 開發中產品的組合

  • 開發平台候補藥相關資訊

第7章 市場環境

  • 市場概要
  • 市場規模與其預測
  • 波特的五力分析

第8章 各類藥物的市場區隔

  • 類鴉片物質
  • 非類固醇系抗發炎藥 (NSAID)
  • 其他

第9章 地區區分

  • 南北美洲市場
  • 歐洲、中東、非洲各國 (EMEA) 市場
  • 亞太地區市場

第10章 推動市場要素

第11章 推動因素的影響力

第12章 市場課題

第13章 推動因素、課題的影響力

第14章 市場趨勢

第15章 供應商環境

  • 競爭方案
  • 市場分析

第16章 供應商環境

  • 其他卓越供應商

第17章 主要供應商分析

  • BioDelivery Sciences
  • ProStrakan
  • Teva Pharmaceuticals

第18章 附錄

  • 簡稱集

第19章 關於Technavio

圖表一覽

目錄
Product Code: IRTNTR7585

About Cancer Pain Therapeutics

Cancer pain can be acute or chronic, depending on its stages and types. Cancer pain is caused by the tumor pressing against bones, nerves, or other organs in an individual's body. Pain control is imperative not only for people who have advanced cancer but also for those whose condition remains stable for years. Pharmaceutical interventions such as non-steroidal anti-inflammatory drugs (NSAIDs), opioids, and adjuvant pain medications are used to treat cancer pain.

Technavio's analysts forecast the global cancer pain therapeutics market to grow at a CAGR of 9.08% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global cancer pain therapeutics market for 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various drugs used in the treatment of cancer pain.

The market is divided into the following segments based on region:

  • Americas: The US, Canada, Mexico, and Brazil
  • EMEA: The UK, Germany, Italy, France, Spain, Israel, South Africa, Egypt, Sudan, Kuwait, Saudi Arabia, Qatar, and the UAE
  • APAC: Japan, China, Australia, Singapore, South Korea, and India

Technavio's report, Global Cancer Pain Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • BioDelivery Sciences
  • ProStrakan Group
  • Teva Pharmaceuticals
  • Yamaha

Other Prominent Vendors

  • Daiichi Sankyo
  • Eli-lilly
  • Galena Biopharma
  • Grunenthal Group
  • GW Pharmaceuticals
  • Hospira
  • Johnson & Johnson
  • Meda Pharmaceuticals
  • Orexo
  • Sanofi
  • Sorrento Therapeutics
  • WEX Pharmaceuticals

Market driver

  • Unmet medical needs
  • For a full, detailed list, view our report

Market challenge

  • Off-label drug use
  • For a full, detailed list, view our report

Market trend

  • Increase in awareness
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Understanding the disease
  • Signs and symptoms
  • Causes of cancer pain
  • Assessment of cancer pain
  • Treatment
  • Epidemiology

PART 06: Pipeline portfolio

  • Information on pipeline candidates

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Five forces analysis

PART 08: Market segmentation by drug class

  • Opioids
  • Non-steroidal anti-inflammatory drugs
  • Others

PART 09: Geographical segmentation

  • Cancer pain therapeutics market in Americas
  • Cancer pain therapeutics market in EMEA
  • Cancer pain therapeutics market in APAC

PART 10: Market drivers

PART 11: Impact of drivers

PART 12: Market challenges

PART 13: Impact of drivers and challenges

PART 14: Market trends

PART 15: Vendor landscape

  • Competitive scenario
  • Market analysis 2014

PART 16: Vendor landscape

  • Other prominent vendors

PART 17: Key vendor analysis

  • BioDelivery Sciences
  • ProStrakan
  • Teva Pharmaceuticals

PART 18: Appendix

  • List of abbreviations

PART 19: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Classification of cancer pain
  • Exhibit 03: Acute pain syndromes
  • Exhibit 04: Chronic pain syndromes
  • Exhibit 05: Causes of pain from cancer
  • Exhibit 06: Causes of pain from procedures and surgery
  • Exhibit 07: Causes of pain from other cancer treatments
  • Exhibit 08: Common causes of pain in cancer patients
  • Exhibit 09: Cancer pain assessment
  • Exhibit 10: Types of pain scales
  • Exhibit 11: Treatment options for cancer pain
  • Exhibit 12: Commonly used non-opioids for pain management
  • Exhibit 13: Commonly used adjuvant medicines for cancer pain
  • Exhibit 14: Management of cancer pain
  • Exhibit 15: Pipeline molecules for cancer pain therapeutics market
  • Exhibit 16: Global cancer pain therapeutics market ($ millions)
  • Exhibit 17: Five forces analysis
  • Exhibit 18: Global cancer pain therapeutics market by drug class
  • Exhibit 19: Global cancer pain therapeutics market by geographical segmentation 2014
  • Exhibit 20: Cancer pain therapeutics market in different regions, 2014-2019 ($ millions)
  • Exhibit 21: Cancer pain therapeutics market in the Americas 2014-2019 ($ millions)
  • Exhibit 22: Cancer pain therapeutics market in EMEA 2014-2019 ($ millions)
  • Exhibit 23: Cancer pain therapeutics market in APAC 2014-2019 ($ millions)
  • Exhibit 24: Impact of drivers
  • Exhibit 25: Impact of drivers and challenges
  • Exhibit 26: BioDelivery Sciences: Key takeaways
  • Exhibit 27: ProStrakan: Key takeaways
  • Exhibit 28: Teva Pharmaceuticals: Key takeaways
  • Exhibit 29: BioDelivery Sciences: Product pipeline
  • Exhibit 30: Teva Pharmaceuticals: Business segmentation by revenue 2014
  • Exhibit 31: Teva Pharmaceuticals: Business segmentation by revenue 2013 and 2014 ($ millions)
  • Exhibit 32: Teva Pharmaceuticals: Geographical segmentation by revenue 2014
Back to Top